common side effects of briellyn
vulvovaginal candidiasis
amenorrhea
breakthrough bleeding
glucose tolerance
headache
increased blood pressure
migraine
spotty menstruation
vaginitis
dizziness
other side effects
abdominal cramps
abdominal distention
acne vulgaris
breast changes
nausea
vomiting
comprehensive list of adverse effects
number of studies
use of oral contraceptives
risk of ovarian cancer
risk of epithelial ovarian cancers
protection against ovarian cancer
years after discontinuation of oral contraceptives
long term use
years
risk of ovarian cancer
risk of endometrial cancer
protection
years after discontinuation
nulliparous women
higher risk for endometrial carcinoma than other women
incidence of hospitalization for pelvic inflammatory disease
women
taking oral contraceptives
reason for the decrease in the frequency
severity
pelvic inflammatory disease in women
taking oral contraceptives
recent studies
decrease in frequency of functional ovarian cysts
older formulations
women
taking newer low dose formulations
recent study
nurses
health study
long term use of oral contraceptives
long term risk for mortality
women
taking oral contraceptive combinations
experienced several non-contraceptive health benefits
benefits
protection
malignant neoplasms
endometrial carcinoma
ovarian cancer
addition
use of oral contraceptive combinations
frequency of benign breast tumors
risk of ovarian cysts
risk of ectopic pregnancy
menstrual regularity
incidence of iron deficiency anemia
incidence of dysmenorrhea
incidence of pelvic inflammatory disease
gastrointestinal side effects
nausea
treated women
first cycles of therapy
early reports
association between oral contraceptive use
gallbladder disease
cases of oral contraceptive-induced esophageal ulceration
geographic tongue
recent studies
risk of gallbladder disease
oncologic side effects
reports
increased risk of invasive breast cancer
large study
n
postmenopausal women
conjugated equine estrogens
medroxyprogesterone
increased risk of coronary heart disease
stroke
pulmonary embolism
number of studies
possible relationship between the use of oral contraceptives
development of breast cancer
studies
reported conflicting results
committee of the world health organization
studies
risks of breast cancer
numerous studies
overall association between oral contraceptive use
risk of breast cancer
addition
same committee
possible relationship between oral contraceptive use
neoplasms of the uterine cervix
insufficient data
firm conclusions
effects
combined oral contraceptives on the risk of cervical adenocarcinoma
"
world health organization committee
studies
weak association between long-term use of oral contraceptives
breast cancer
age
age
observed association
bias
development of new cases of cancer
accelerated growth
existing cancers
world health organization committee
increased risk of breast cancer in women over the age
taken oral contraceptives
addition
studies
use of oral contraceptives
specific groups of women
family history of breast cancer
lower risk
variations in the hormonal content of oral contraceptives
risk of breast cancer
studies
potential risk of cervical cancer in patients
taking oral contraceptives
large number of confounding factors
investigations into the epidemiology of this neoplasm
studies
women
taking oral contraceptives
increased risk of dysplasia
epidermoid carcinoma
adenocarcinoma of the cervix
other studies
association
detailed information
effects of oral contraceptive therapy on lipid metabolism
endocrine paragraph of this side effect monograph
early investigations of women
taking high dose estrogen combinations
mcg
ethinyl estradiol
such women
increased risk of cardiovascular complications
myocardial infarction
stroke
vascular thrombosis
including
venous thromboembolism
recent large investigations of women
taking low dose estrogen combinations
oral contraceptive use
increased risk of serious cardiovascular complications in healthy non smoking women
age
women
preexisting
preexisting systemic diseases
cardiovascular system
use of oral contraceptives
investigators
new low dose products
adverse effects on lipid metabolism
careful review of a woman
cardiovascular risk factors before a decision
oral contraceptive combinations
frequency of both subarachnoid hemorrhage
thrombotic stroke
investigators
women
taking oral contraceptive hormones
other investigators
risk of these effects for women
using newer low dose formulations
young women
underlying
underlying cardiovascular disease
other risk factors
cardiovascular
side effects
reports
increased risk of coronary heart disease
stroke
pulmonary embolism
large study
n
postmenopausal women
conjugated equine estrogens
medroxyprogesterone
increased risk of coronary heart disease
stroke
pulmonary embolism
earlier studies
unopposed estrogen therapy
risk of coronary heart disease
combination therapy with a progestin
coronary risk
cardiovascular
side effects of the estrogen component of this combination
reports of hypertension
significant blood pressure increases
women
receiving high-dose estrogen products
mcg
ethinyl estradiol
estrogens
edema
addition
exogenous estrogens
cardioprotective effects
causing
causing favorable changes in lipid profiles
beneficial effects
alterations in lipid profiles
exogenous progestins
endocrine side effects
reports of complex alterations in plasma lipid profiles
carbohydrate metabolism
addition
oral contraceptive use
conception delay
progestins
available oral contraceptive combinations
adverse effects on lipid profiles
progestins
antiestrogen
androgen effects
hdl
hdl
cholesterol levels
increase ldl cholesterol levels
estrogens in oral contraceptive combinations
opposing effects
alterations in lipid profiles
relative amount
potency of the specific estrogen
progestin in a
given product
norethindrone
moderate androgen effect
weak progestin
antiestrogen effects
number of investigations
oral contraceptive combinations
glucose tolerance
recent studies with low dose preparations
glucose tolerance
oral contraceptive combinations
adverse effects of oral contraceptives on lipid levels
glucose tolerance
investigators
young diabetic women
existing
existing vascular disease
severe lipidemias
candidates for low dose
oral contraceptive combinations
close monitoring for adverse metabolic effects
hepatic side effects
focal nodular hyperplasia
intrahepatic cholestasis
liver cell adenomas
hepatic granulomas
hepatic hemangiomas
well-differentiated hepatocellular carcinomas
association with estrogen therapy
therapy with oral contraceptive combinations
rate of death
hepatocellular carcinoma in the united states
last years
time during which use of oral contraceptive hormones
committee of the world health organization
developing countries
hepatitis b virus infection
hepatocellular carcinoma
short term use of oral contraceptives
increased risk
data on the effects of long term use
recent italian case-control study of women with hepatocellular carcinoma
relative risk of hepatocellular carcinoma
oral contraceptive users
women
oral contraceptives
similar american case-control study
strong association between oral contraceptive use
hepatocellular carcinoma
observed association
actual number of cases of liver cancer in the united states
oral contraceptive use
findings
public health importance in the united states
other western nations
"
cases of venous thrombosis
pulmonary embolism
arterial thrombosis
previous thrombotic disease
contraindication
oral contraceptive combinations
hematologic side effects
risk of thromboembolism
use of exogenous estrogens
dose of exogenous estrogens
available preparations
risk of thromboembolism
most women
women
age
smoke
women with a history of previous thrombotic diseases
genitourinary side effects
breakthrough bleeding
spotting
first several cycles of oral contraceptive use
non-hormonal causes of such bleeding
additional side effects
estrogen
progestin therapy
changes in vaginal bleeding pattern
abnormal withdrawal bleeding
flow
increase in size of uterine leiomyomata
vaginal candidiasis
change in amount of cervical secretion
change in cervical ectropion
ovarian cancer
endometrial hyperplasia
endometrial cancer
vaginitis
women experience oligomenorrhea
amenorrhea
following termination
oral contraceptive use
psychiatric side effects
depression
precipitation of panic disorder
immunologic side effects
rare cases of oral contraceptive-induced systemic lupus erythematosus
nervous system
side effects
chorea
association with oral contraceptives
ocular side effects
rare cases of retinal thrombosis
addition
manufacturers of oral contraceptive products
patients
changes in contact lens tolerance
respiratory side effects
reports
increased risk of pulmonary embolism
large study
n
postmenopausal women
conjugated equine estrogens
medroxyprogesterone
increased risk of coronary heart disease
stroke
pulmonary embolism
case of fatal pulmonary venooclusive disease
oral contraceptive therapy
oral capsule liquid
oral tablet
oral tablet
breast tenderness
heavy non-menstrual vaginal bleeding
irregular menstrual periods
heavier menstrual periods
normal menstrual bleeding
lasting
chest pain
chills
clay-colored stools
confusion
dark urine
diarrhea
difficulty with speaking
dizziness
double vision
irregular heartbeat
fever
headache
inability
arms
legs
facial muscles
inability to speak
indigestion
itching or rash
loss of appetite
nausea
pain
redness
swelling in the arm
leg
pains in the chest
groin
legs
calves of the legs
severe headaches of sudden onset
severe nausea
vomiting
slurred speech
stomach pain
sudden loss of coordination
sudden onset of shortness of breath for no apparent reason
sudden onset of slurred speech
sudden vision changes
tightness in the chest
unpleasant breath odor
unusual tiredness
weakness
unusual warmth
flushing of the skin
unexpected menstrual bleeding
vaginal bleeding
spotting
vomiting of blood
yellow eyes
skin
vomiting
anxiety
blemishes on the skin
cramps
depression
heavy bleeding
pain
pimples
weight changes